The dispute between generic drugmakers Apotex and Teva stemming from a former Teva executive’s alleged disclosure of trade secrets to an Apotex CEO while the two were dating is heating up, with the parties now sparring over the speed of discovery.
Shortly after Teva filed its lawsuit, which alleged its former senior director of regulatory affairs gave confidential information to Apotex CEO Jeremy Desai, Teva asked the U.S. District Court for the Eastern District of Pennsylvania to expedite discovery to determine the full extent of the information that was shared.
